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ABSTRACT
Introduction: Treatment with glucagon-like
peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors, which target the
incretin axis, has the potential to improve
glycemic control in type 2 diabetes patients
without the weight gain associated with
traditional therapies. To evaluate the relative
cost-effectiveness of incretin therapies, the
present study aimed to compare the long-term
clinical and cost implications associated with
liraglutide and sitagliptin in type 2 diabetes
patients in Spain.
Methods: Data were taken from a randomized,
controlled trial (NCT00700817) in which adults
with type 2 diabetes failing metformin
monotherapy were randomly allocated to
receive either liraglutide 1.2 mg or sitagliptin
100 mg daily in addition to metformin. Long-
term projections of clinical outcomes and direct
costs (2012 EUR) based on observed treatment
effects were made using a published and
validated type 2 diabetes model. Costs were
taken from published sources. Future costs and
clinical benefits were discounted at 3%
annually. Sensitivity analyses were performed.
Results: Liraglutide was associated with
improved discounted life expectancy (14.05
versus 13.91 years) and quality-adjusted life
expectancy [9.04 versus 8.87 quality-adjusted
life years (QALYs)] compared to sitagliptin.
Improved clinical outcomes were driven by
improved glycemic control, leading to reduced
incidence of diabetes-related complications,
including renal disease, cardiovascular disease,
ophthalmic and diabetic foot complications.
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Liraglutide was associated with increased direct
costs of EUR 2,297, yielding an incremental
cost-effectiveness ratio of EUR 13,266 per
QALY gained versus sitagliptin.
Conclusions: Liraglutide was projected to
improve life expectancy, quality-adjusted life
expectancy and reduce incidence of diabetes-
related complication. Liraglutide is likely to be
cost-effective versus sitagliptin from a
healthcare payer perspective in Spain.
Keywords: Cost; Cost-effectiveness; DPP-4;
GLP-1; Incretin; Liraglutide; Sitagliptin; Spain;
Type 2 diabetes
INTRODUCTION
Diabetes mellitus represents a significant and
growing challenge to healthcare providers in
Spain, with a current prevalence of 13.8%,
around half of which is undiagnosed, and
almost 30% of the population has some form
of carbohydrate metabolism disturbance [1].
The disease is associated with a significant
clinical burden, both in terms of morbidity
and mortality, with 19,518 deaths attributable
to diabetes in Spain in 2010 [2]. Further to the
clinical burden, the economic burden is also
substantial. Current estimates suggest that
diabetes is responsible for between 5% and
13% of total healthcare expenditure in most
developed countries, and Spain is no exception
[2]. Health care expenditure as a result of
diabetes mellitus was estimated to be
approximately USD 12.5 billion in Spain in
2010 (9% of total healthcare expenditure), and
projections suggest that this could increase to
approximately USD 16.5 billion in 2030 [3]. The
principle driver of this expenditure is diabetes-
related complications.
Whilst maintaining glycemic control forms
the cornerstone of diabetes treatment, evidence
suggests that controlling other risk factors is
also important in reducing the long-term risk of
complications. This includes serum lipid levels,
blood pressure and body weight. The benefits of
multifactorial intervention have been
demonstrated in a number of trials, but
particularly the Steno-2 study, which
compared conventional treatment for multiple
risk factors versus intensive multifactorial
treatment [4–6]. Intensive treatment was
associated with reduced risk of all-cause
mortality, cardiovascular events, retinopathy,
neuropathy and end-stage renal disease over
13 years of follow-up. Most long-established
diabetes interventions are designed to improve
glycemic control, but do little to address other
risk factors and meet the multifaceted needs of
the type 2 diabetes patient [7].
To meet these complex clinical needs,
clinical development programs have targeted
the modulation of incretin activity
(gastrointestinal hormones involved in the
regulation of gut motility, secretion of gastric
acid and pancreatic enzymes, gall bladder
contraction and nutrient absorption) [8]. This
has led to the development of two new classes
of antidiabetic therapy: degradation-resistant
glucagon-like peptide-1 (GLP-1) receptor
agonists, such as liraglutide and exenatide,
and inhibitors of dipeptidyl peptidase-4 (DPP-
4), such as sitagliptin and vildagliptin. Data
from published studies indicate that GLP-1
receptor agonists may be associated with a
more substantial reduction in glycated
hemoglobin (HbA1c) in comparison with DPP-
4 inhibitors (0.5–1.6% reduction versus
0.5–1.0% reduction) [7]. Weight loss has been
shown to be associated with liraglutide and
exenatide treatment [9–14], whereas DPP-4
inhibitors are weight neutral and have been
associated only with the prevention of weight
gain [15–18].
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Although there is a growing body of clinical
data available on these new agents, and several
health economic analyses have been published
comparing them with long-established
interventions, there is a paucity of data on the
cost-effectiveness of GLP-1 receptor agonists in
comparison with DPP-4 inhibitors. The aim of
the present analysis was to assess the cost-
effectiveness of liraglutide versus sitagliptin, as
add-on to metformin therapy, in patients
failing metformin alone in the Spanish setting.
METHODS
Simulated Cohort and Treatment Effects
In 2010, Pratley et al. [9] reported a parallel-
group, open-label trial in participants (aged
18–80 years) with type 2 diabetes mellitus who
had inadequate glycemic control (HbA1c
7.5–10.0%) on metformin (C1,500 mg daily for
C3 months) designed to compare the efficacy
and safety of liraglutide and sitagliptin. Patients
were randomly allocated to 1.2 mg subcutaneous
liraglutide once daily (n = 225), or 100 mg oral
sitagliptin once daily (n = 219) at sites in Europe
(including 9 centers and 32 participants in Spain)
and North America. Main exclusion criteria
included body mass index over 45 kg/m2,
previous treatment with any antihyperglycemic
agent apart from metformin within 3 months of
the trial, recurrent major hypoglycemia or
hypoglycemic unawareness, present use of any
drug except metformin that could affect glucose
metabolism, impaired renal or hepatic function,
clinically significant cardiovascular disease, or
cancer. Baseline patient cohort characteristics,
based on the population enrolled in the study,
are shown Table 1.
After 26 weeks of follow-up, both liraglutide
and sitagliptin were associated with
improvements in HbA1c, systolic blood
pressure, blood lipid levels and body mass
index (BMI). Treatment effects were applied in
the first year of the analysis based on the clinical
trial data (Table 2). Hypoglycemia rates were
similar in the two arms of the trial, although
one major hypoglycemic event was reported in
the liraglutide arm, but none in the sitagliptin
arm. Patients were assumed to receive
liraglutide or sitagliptin for 5 years, before
intensifying treatment to basal insulin
(incretin therapy withdrawn). On treatment
intensification, BMI was assumed to return to
baseline and hypoglycemia event rates were
assumed to be the same, but no other treatment
effects were applied.
Model Description
The analysis was performed using the CORE
Diabetes Model (IMS Health, Basel,
Table 1 Baseline characteristics of the simulation cohort
Characteristic Value, mean (SD)
Age (years) 55.3 (9.2)
Duration of diabetes (years) 6.0 (4.5)
Males (%) 52.9
HbA1c (%) 8.4 (0.8)
SBP (mmHg) 132.2 (14.6)
Total cholesterol (mmol/L) 4.09 (1.14)
HDL cholesterol (mmol/L) 1.16 (0.31)
LDL cholesterol (mmol/L) 2.65 (0.82)
Triglycerides (mmol/L) 2.38 (2.22)
Body mass index (kg/m2) 32.8 (5.2)
Smokers (%) 29.5
Baseline characteristics are the weighted mean of patients
enrolled in the liraglutide 1.2 mg and sitagliptin arms of
the study
HbA1c glycated hemoglobin, HDL high-density
lipoprotein, LDL low-density lipoprotein, SD standard
deviation, SBP systolic blood pressure
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Switzerland), the architecture, assumptions,
features and capabilities of which have been
previously published [10]. The model is a
validated, non-product-specific diabetes policy
analysis tool and is based on a series of inter-
dependent sub-models that simulate the
complications of diabetes (angina, myocardial
infarction, congestive heart failure, stroke,
peripheral vascular disease, diabetic
retinopathy, macular edema, cataract,
hypoglycemia, ketoacidosis, lactic acidosis,
nephropathy and end-stage renal disease,
neuropathy, foot ulcer and amputation, and
non-specific mortality). Each sub-model has a
semi-Markov structure and uses time, state,
time-in-state and diabetes type-dependent
probabilities derived from published sources.
Monte Carlo simulation using tracker variables
overcomes the memory-less properties of the
standard Markov model, and allows
interconnectivity and interaction between
individual complication sub-models. Long-
term outcomes projected by the model have
been validated against real life data in 2004 and
more recently in 2012 [11, 12].
Costs and Utilities
Costs were accounted from the perspective of a
healthcare payer in Spain (i.e., Sistema Nacional
de Salud) in 2012 Euros (EUR). The Spanish
health system has the characteristics of the
‘‘Beveridge Model’’ since it is mostly funded by
direct taxation, it covers the resident
population on the basis of citizenship and the
provision of services is mostly made by public
units. The costs of diabetes medications, self-
monitoring of blood glucose, concomitant
medications (statins, aspirin and angiotensin-
converting enzyme inhibitors), and diabetes-
related complications were captured. Costs were
identified through literature review and came
from diagnosis-related group tariffs released by
the Spanish Ministry for Health, and published
cost collection studies, with inflation to 2012
values as required [13–21]. Health-related
Table 2 Treatment effects applied in the ﬁrst year of the analysis





Change in HbA1c (%) -1.24 (1.02) -0.90 (1.01) -0.34*
Change in SBP (mmHg) -0.55 (12.99) -0.94 (12.99) 0.39
Change in total cholesterol (mmol/L) -0.03 (0.82) -0.02 (0.80) -0.01
Change in HDL cholesterol (mmol/L) 0.00 (0.17) 0.00 (0.17) 0.00
Change in LDL cholesterol (mmol/L) 0.08 (0.69) 0.13 (0.68) -0.05
Change in triglycerides (mmol/L) -0.19 (1.42) -0.40 (1.38) 0.21
Change in body mass index (kg/m2) -0.99 (1.37) -0.33 (1.37) -0.66*
Major hypoglycemic events (per 100 patient years) 1.00 0.00 1.00
Minor hypoglycemic events (per 100 patient years) 17.80 10.60 7.20
HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, SBP systolic blood pressure,
SD standard deviation
* p\0.001
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quality of life utilities associated with diabetes-
related complications were as per a previous
cost-effectiveness analysis of liraglutide versus
sitagliptin, carried out in the UK setting [22].
Statistical Approach and Other Model
Settings
A simulated cohort of 1,000 patients was run
through the model 1,000 times for each
simulation (base case and sensitivity analysis).
Mean values and standard deviations were
generated for long-term outcomes. A total of
1,000 mean values (each from 1,000 patients) of
incremental direct medical costs and
incremental effectiveness in terms of quality-
adjusted life expectancy were plotted
(scatterplots) on a cost-effectiveness plane.
Subsequently, acceptability curves were
generated by calculating the proportion of
points below a range of willingness to pay
thresholds (up to EUR 100,000 per QALY
gained). The time horizon was set to patient
lifetimes in the base case to capture all relevant
long-term complications and associated costs,
to assess their impact on life expectancy and
quality-adjusted life expectancy. Future costs
and clinical benefits were discounted
symmetrically by 3% per annum in line with
published health economic guidance for
Spain [23].
Sensitivity Analyses
A series of one-way sensitivity analyses were
conducted to identify key drivers of outcomes
and assess the robustness of results of the base
case analysis. The influence of time horizon
on the outcomes projected by the model was
investigating by running analyses over 5, 10,
20 and 30 years, compared to 50 years in the
base case. Similarly, the effect of discount rates
on future costs and clinical outcomes were
investigated through analyses in which they
were set (symmetrically) to 0% and 5% per
annum. The effect of over- or underestimating
the unit costs of diabetes complications used
in the analysis was evaluated in two sensitivity
analyses, which increased and decreased the
values used by 10% from the base case costs.
The importance of changes in physiological
parameters were investigated in four
sensitivity analysis, in which benefits in
HbA1c, systolic blood pressure, blood lipids
and BMI were individually abolished. A further
analysis was conducted in which HbA1c was
assumed to progress according to the UK
Prospective Diabetes Study (UKPDS)
progression curve before switching to basal
insulin. The effect of the timing of treatment
switching was examined by varying the
treatment switch to 7 and 3 years in the
liraglutide arm.
As part of the follow-up to the clinical
trial, patients receiving sitagliptin were given
the option of switching to liraglutide
following completion of the initial study
period [24]. Patients were then followed for a
further 26 weeks. On switching to 1.2 mg
liraglutide, improvements were seen in
HbA1c, systolic blood pressure, blood lipid
profiles and BMI, in addition to the changes
seen on starting sitagliptin therapy. An
analysis was conducted in which patients
received sitagliptin for 1 year, and then
switched to liraglutide. As in the base case,
patients switched to basal insulin after 5 years
of incretin therapy.
Compliance with Ethics
This article does not contain any studies with
human or animal subjects performed by any of
the authors.




Therapy with once daily liraglutide 1.2 mg was
associated with a mean undiscounted life
expectancy of 20.00 years (SD 0.33) compared
to 19.72 years (0.30) with once daily 100 mg
sitagliptin (Table 3). Analysis of discounted life
expectancy showed a similar pattern, with
liraglutide associated with a statistically
significant increase of 0.14 years compared to
sitagliptin (14.05 versus 13.91 years). Liraglutide
was also associated with increased mean quality-
adjusted life expectancy, from 8.87 quality-
adjusted life years (QALYs) (95% confidence
interval 8.86–8.88 QALYs) with sitagliptin to
9.04 QALYs (95% confidence interval 9.03–9.05
QALYs). These clinical benefits were primarily
driven by improved glycemic control leading to
a reduced incidence of diabetes-related
complications in the liraglutide arm. End-stage
complications, including severe vision loss, end-
stage renal disease, amputation and myocardial
infarction, had the greatest impact on patient
health-related quality of life, and the cumulative
incidence of these complications showed
significant reductions in the liraglutide arm.
This included macrovascular complications,
with the cumulative incidence of myocardial
infarction reduced from 27% to 25%, and
microvascular complications, with the
cumulative incidence of background diabetic
retinopathy reduced from 17% to 15%. The only
complication that showed an increased
incidence in the liraglutide arm was stroke. As
well as a reduced incidence of complications,
liraglutide was also associated with delayed
onset of complications, with the mean time
free of all complications increased by almost
7 months. Of particular note was the mean time
to onset of stroke, which was delayed by
9 months in the liraglutide arm, demonstrating
the influence of the survival paradox.
Direct costs were projected to increase by
EUR 2,297 per patient in the liraglutide arm
(EUR 54,684 in the liraglutide arm versus
EUR 52,387 in the sitagliptin arm) (Table 3;
Fig. 1). This increase was driven by the
increased acquisition costs of liraglutide
compared to sitagliptin in the first 5 years of
the simulation. However, this was partially
offset by the reduced costs of treating diabetes-
related complications. The most notable savings
were made as a result of avoided neuropathy
complications, where treatment with liraglutide
was associated with cost savings of EUR 1,110
per patient. Based on these estimates, liraglutide
was associated with an incremental cost-
effectiveness ratio (ICER) of EUR 13,266 per






Undiscounted life expectancy (years) 20.00 (0.33) 19.72 (0.30) 0.28
Discounted life expectancy (years) 14.05 (0.19) 13.91 (0.17) 0.14
Discounted quality-adjusted life expectancy (QALYs) 9.04 (0.13) 8.87 (0.11) 0.17
Discounted direct costs (EUR) 54,684 (1,250) 52,387 (1,346) 2,297
ICER (EUR per QALY gained) 13,266
EUR 2012 Euros, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, SD standard deviation
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QALY gained compared to sitagliptin in Spain.
This is below the commonly quoted willingness
to pay threshold of EUR 30,000 per QALY
gained. A scatterplot presenting the
incremental costs versus incremental
effectiveness for liraglutide versus sitagliptin
shows 1,000 mean values, each representing a
cohort of 1,000 patients run through the model
is shown in Fig. 2. Data from the scatterplot was
used to generate an acceptability curve, which
showed that at a willingness to pay threshold of
EUR 30,000 per QALY gained, there was a 73%
probability that liraglutide would be cost-
effective in comparison with sitagliptin.
Sensitivity Analyses
Sensitivity analyses found that cost-
effectiveness outcomes were most sensitive to
changes in the HbA1c benefit associated with
liraglutide (Table 4). When this benefit was
abolished the ICER was found to increase to
EUR 199,114 per QALY gained. The impact of
changes in HbA1c was also demonstrated in the
analysis in which the UKPDS progression curve
was used. The ICER increased to EUR 29,012 per
QALY gained, remaining below the EUR 30,000
per QALY gained threshold, as the HbA1c
benefit in the liraglutide arm was not
sustained. Changes in other physiological
parameters had smaller impacts on the ICER,
although making BMI changes equal in the two
arms increased the ICER to EUR 16,931 per
QALY gained.
Shortening the time horizon also had a
significant impact on the ICER. This was
primarily due to the fact that improvements in


























Fig. 1 Discounted direct medical costs associated with liraglutide and sitagliptin over patient lifetimes. EUR 2012 Euros
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liraglutide reduce the risk of long-term
complications, and the benefits of this are not
fully realized over shorter time horizons.
Interestingly, over a 30-year time horizon, the
ICER was lower than in the base case analysis
(50-year time horizon). This is due to the
increased survival in the liraglutide arm,
increasing mean life expectancy, and therefore
greater costs are accrued in the liraglutide arm
in the later years of the analysis. Altering the
discount rate also reflected the long-term
benefits associated with liraglutide, with
incremental quality-adjusted life expectancy
increasing to 0.29 QALYs and incremental
costs falling to EUR 1,877 when a discount
rate of 0% was used. Changing the timing of
treatment switching led to changes in the ICER.
It was found to increase when patients received
incretin therapy for 7 years, due to the increased
acquisition costs of liraglutide, and fell when
treatment switching was brought forward.
Increasing the cost of complications led to a
small decrease in the ICER, whilst the converse
was true when the cost of complications was
reduced.
Switching patients to liraglutide after 1 year
of sitagliptin treatment was found to improve
clinical outcomes compared to remaining on
sitagliptin. Mean life expectancy was increased
by 0.11 years, and quality-adjusted life
expectancy by 0.13 QALYs (Table 4). However,
these increases compared to sitagliptin were not
as large as in the base case analysis, where
patients received liraglutide in the first year of
the analysis. This was driven by smaller
improvements in physiological parameters on
delayed initiation of liraglutide compared to
immediate initiation. Direct costs were higher
in the delayed liraglutide arm than in the




















Incremental quality-adjusted life expectancy (QALYs)
EUR 30,000 per
QALY gained
Fig. 2 Scatterplot of incremental costs versus incremental effectiveness of liraglutide 1.2 mg versus sitagliptin.
EUR 2012 Euros, QALY quality-adjusted life year
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EUR 52,387). As in the base case, increased costs
were driven by the acquisition of liraglutide in
years two to five of the analysis, but were
partially offset by the reduced cost of treating
diabetes-related complications. The ICER of
EUR 16,287 per QALY gained is higher than in
the base case analysis. The results of this sub-
analysis, in conjunction with the base case,
indicate that starting patients on liraglutide
earlier is associated with improved outcomes
compared to the delayed initiation scenario,
and does so at a lower ICER. Initiating


















Base case 9.04 8.87 0.17 54,684 52,387 2,297 13,266
30-year time horizon 8.89 8.72 0.17 51,435 49,219 2,216 12,813
20-year time horizon 8.05 7.92 0.13 41,822 39,270 2,552 19,495
10-year time horizon 5.36 5.30 0.06 23,431 20,029 3,402 58,433
5-year time horizon 3.07 3.04 0.04 13,309 9,507 3,802 102,605
0% discount rate 12.58 12.30 0.29 85,633 83,755 1,877 6,547
5% discount rate 7.50 7.37 0.13 42,626 40,181 2,445 18,753
Costs of complications
plus 10%
9.04 8.87 0.17 58,268 56,147 2,121 12,248
Costs of complications
minus 10%
9.04 8.87 0.17 51,277 48,805 2,473 14,279
No HbA1c difference 8.89 8.87 0.02 56,315 52,387 3,928 199,114
No SBP difference 9.04 8.87 0.18 54,672 52,387 2,285 13,087
No lipid difference 9.04 8.87 0.17 54,683 52,387 2,296 13,288
No BMI difference 9.00 8.87 0.14 54,675 52,387 2,288 16,931
No hypoglycemia difference 9.05 8.87 0.18 54,758 52,387 2,371 13,127
UKPDS creep for
5 years
8.71 8.59 0.11 59,289 55,991 3,297 29,012
Treatment switch
after 7 years
9.05 8.87 0.18 55,889 52,387 3,502 19,019
Treatment switch after
3 years
9.02 8.87 0.16 53,339 52,387 952 6,115
Receive sitagliptin
for 1 year before
switching to liraglutide
8.99 8.87 0.13 54,444 52,387 2,057 16,287
EUR 2012 Euros, HbA1c glycated hemoglobin, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year,
SBP systolic blood pressure, UKPDS United Kingdom Prospective Diabetes Study
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liraglutide earlier shows extended dominance
over delaying initiation of liraglutide therapy by
1 year.
DISCUSSION
The present long-term cost-effectiveness
modeling analysis indicates that liraglutide
1.2 mg is associated with improved clinical
outcomes, in terms of life expectancy, quality-
adjusted life expectancy and avoidance of
diabetes-related complications, in comparison
to sitagliptin. Sensitivity analysis identified that
improved glycemic control, manifest by
reduced HbA1c, is the key driver of the clinical
benefit (as identified by the sensitivity
analyses), but improvements in other
physiological parameters play a role in
reducing the long-term risk of diabetes-related
complications. The increased incidence of
stroke observed is likely to be due to the
survival paradox, where an increased number
of events are seen in the liraglutide arm due to
the increased life expectancy. Liraglutide was
associated with increased direct medical costs,
driven by the acquisition cost of liraglutide but
this was partially offset by the reduced cost of
treating diabetes-related complications. Based
on the calculated ICER, once daily 1.2 mg
liraglutide is likely to be cost-effective
compared to one daily 100 mg sitagliptin in
Spain. A sub-group analysis found that delaying
liraglutide therapy by 1 year resulted in less
favorable clinical outcomes compared to
initiating liraglutide earlier, although cost
savings could be made as a result. The present
analysis compares the 1.2 mg daily dose of
liraglutide with sitagliptin, as this is the most
commonly prescribed dose in Europe. However,
a 1.8 mg daily dose is also available, and data
from the clinical trial published by Pratley et al.
[9] suggest that the higher dose may be
associated with greater clinical benefits than
the 1.2 mg dose.
Whilst metformin remains the first-line
therapy option for patient with type 2
diabetes, modulation of incretin activity,
through addition of a GLP-1 receptor agonist
or a DPP-4 inhibitor, represents a potential
second-line therapy option for patients failing
to achieve glycemic control on metformin
monotherapy. The GLP-1 receptor agonists
and DPP-4 inhibitors offer alternatives to long-
standing second-line treatment options, such as
sulphonylureas (associated with increased risk
of hypoglycemic events and modest weight
gain) or thiazolidinediones (associated with
cardiovascular risk, weight gain, edema and
fractures) [25]. Modern treatment of type 2
diabetes is based around maintaining glycemic
control, but also addressing the comorbidities
associated with diabetes, specifically obesity,
hypertension and dyslipidemia and the trial
data published by Pratley et al. [9] suggest that
liraglutide and sitagliptin may be useful in
terms of managing a variety of risk factors.
Through maintaining this multifactorial
control, the risk of long-term diabetes-related
complications can be reduced, thereby reducing
the burden of diabetes.
Previous cost-effectiveness analyses have
compared GLP-1 receptor agonists and DPP-4
inhibitors with conventional second line
treatments, but only two other published
studies have compared liraglutide and
sitagliptin. The results of the present analysis
agree with these previous cost-effectiveness
analyses, carried out from the perspective of
healthcare payers in the United Kingdom and
United States. Davies et al. [22] found that
liraglutide was associated with an ICER of
GBP 9,851 per QALY gained (below a
willingness to pay threshold of GBP 20,000 per
QALY gained threshold), while Lee et al. [26]
426 Diabetes Ther (2013) 4:417–430
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calculated an ICER of USD 25,742 per QALY
gained (below a willingness to pay threshold of
USD 50,000 per QALY gained) versus sitagliptin.
The results across the United Kingdom, United
States and Spain suggest that liraglutide may be
a cost-effective treatment option in all three
settings.
The present analysis found that liraglutide
was associated with reduced cumulative
incidence and delayed onset of neuropathy
compared to sitagliptin. There is evidence
from animal models suggesting that increased
circulating GLP-1 (either through
administration of a DPP-4 inhibitor or a GLP-1
receptor agonist) may reduce neuropathy,
independent of glycemic control [27].
However, this research is at a very early stage,
and how the potential benefit will manifest in
humans, rather than animals is, as yet,
unknown.
A further consideration is how generalizable
the population of the trial reported by Pratley
et al. is to the Spanish setting. The diabetes
mellitus group of the Sociedad Espan˜ola de
Endocrinologı´a y Nutricio´n (Spain
Endocrinology and Nutrition Society, SEEN)
has conducted a retrospective study of GLP-1
receptor agonists in clinical practice [28]. The
baseline characteristics of this real-world
population match well to the baseline
characteristics of the trial participants on
which the present analysis is based, in terms
of age, duration of diabetes, HbA1c, systolic
blood pressure and blood lipid measurements.
However, the BMI of patients currently
receiving liraglutide in Spain is a little higher
than in the clinical trial (38.0 kg/m2 compared
to 32.8 kg/m2). It may be the case that
liraglutide will be associated with greater
weight loss in these patients, and therefore
liraglutide may be more cost-effective in this
population.
A potential limitation of the analysis may be
the robustness of the input data from the
clinical trials. Both the original study and the
extension study where the patients were
switched from sitagliptin to liraglutide were
open-label trials, owing to the nature of
comparison of an oral agent with an injection.
This may have led to patients having different
expectations of the effects of liraglutide or
sitagliptin, which potentially may have
influenced adherence to lifestyle
recommendations. Although the extent of any
such effect is difficult to assess, it is reassuring
that the efficacy findings are in line with the
results of other head-to-head trials comparing
GLP-1 receptor agonists with DPP-4 inhibitors.
For example, when exenatide once-weekly
(Diabetes Therapy Utilization: Researching
Changes in A1C 2, DURATION-2) or
taspoglutide (T-emerge 4) were compared with
sitagliptin over 26 weeks, HbA1c was reduced by
1.5% and 1.3% with exenatide once-weekly and
taspoglutide, respectively, compared with 0.9%
with sitagliptin [29, 30]. Weight loss with
sitagliptin was a little better in the Pratley
et al. [9] trial than in previous studies where it
has been generally shown to be weight neutral.
The impact of adherence to the two diabetes
medications evaluated should be considered.
Whilst adherence to alternative GLP-1 receptor
agonists has been assessed, currently, there is no
evidence to suggest that injectable GLP-1
receptor agonists are associated with lower
adherence rates than oral DPP-4 inhibitors [31,
32]. Moreover, the impact of adherence on cost-
effectiveness is difficult to assess, as both
clinical outcomes and costs will be affected by
adherence rates.
A further limitation of the present analysis is
the reliance on short-term clinical data in
making long-term predictions of outcomes
over time horizons of up to 50 years. However,
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this is a limitation inherent to most cost-
effectiveness modeling studies, and despite
this, such studies represent one of the best
available options for making estimates of long-
term clinical and economic outcomes in the
absence of long-term clinical data. The
generalizability of the risk equations used in
modeling analyses must also be considered,
with data (such as that from the UKPDS) now
historic and perhaps not representative of
modern diabetes treatment in Spain. As a
result, there is unavoidable uncertainty around
how well the modeling analysis represents the
real world. The present study aims to minimize
this limitation, through use of a recently
validated model to conduct the analysis, and
basing changes in physiological parameters on
data collected in a randomized controlled trial
[9, 11, 12]. Furthermore, the use of QALYs in
health economic analysis remains a somewhat
controversial issue. Some argue that
assumptions that underlie the QALY concept
are often broken, and other measures (such as
the healthy year equivalent) are more
appropriate [33]. The Glycemia Reduction
Approaches in Diabetes (GRADE) study will
aim to provide long-term data on the relative
effectiveness of diabetes medications in patients
failing metformin therapy, including liraglutide
and sitagliptin [34]. This 5,000-patient, 7-year
study will provide a wealth of data for health
economic analysis, and will be a key data source
for future economic evaluation when the study
reports in 2020.
CONCLUSION
The recent 26-week study investigating the
safety and efficacy of liraglutide and sitagliptin
published by Pratley et al. [9] indicated that
liraglutide was associated with greater
improvements from baseline HbA1c, total
cholesterol and BMI compared to sitagliptin.
Long-term projections of this short-term trial
data using a recently validated model suggest
that liraglutide is likely to improve survival,
reduce complication rates and be cost-effective
from the perspective of a healthcare payer in
Spain.
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